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The introduction of C4d in daily clinical practice in the late
nineties aroused an ever-increasing interest in the role of
antibody-mediated mechanisms in allograft rejection. As a
marker of classical complement activation, C4d made it
possible to visualize the direct link between anti-donor
antibodies and tissue injury at sites of antibody binding
in a graft. With the expanding use of C4d worldwide several
limitations of C4d were identified. For instance, in ABO-
incompatible transplantations C4d is present in the majority
of grafts but this seems to point at ‘graft accommodation’
rather than antibody-mediated rejection. C4d is now
increasingly recognized as a potential biomarker in other
fields where antibodies can cause tissue damage, such as
systemic autoimmune diseases and pregnancy. In all these
fields, C4d holds promise to detect patients at risk for the
consequences of antibody-mediated disease. Moreover, the
emergence of new therapeutics that block complement
activation makes C4d a marker with potential to identify
patients who may possibly benefit from these drugs. This
review provides an overview of the past, present, and future
perspectives of C4d as a biomarker, focusing on its use in
solid organ transplantation and discussing its possible
new roles in autoimmunity and pregnancy.
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In the 1950s it was generally accepted that allograft
rejection occurred due to T-cell–mediated cellular cyto-
toxicity. The introduction of C4d staining in daily clinical
practice in the late nineties aroused an ever-increasing
interest in the role of antibody-mediated mechanisms in
allograft rejection. C4d as a marker made it possible to
visualize, for the first time, the direct link between anti-
donor antibodies and tissue injury at sites of antibody
binding. It is illustrative that C4d as a biomarker has been
called ‘a magic marker’, because of its stability, its strong
association with antibody-mediated rejection (AMR), and
finally, its major impact on graft survival and patient
treatment.1
However, with the expanding use of C4d by transplant
pathologists worldwide, several shortcomings of C4d were
identified, and C4d appeared to be a less-sensitive marker
than initially thought. For instance, in ABO-incompatible
transplantations C4d is present in the majority of grafts, but
this does not seem to be alarming, and certainly does not
seem to indicate acute AMR or an inferior graft prognosis.2
In addition, molecular studies provided insight, suggestive
of a complement-independent form of AMR or C4d-negative
AMR, in which C4d is obviously not helpful as a diagnostic
tool.3
C4d is now increasingly recognized as a potential
biomarker in other fields where antibodies can cause tissue
damage, such as systemic autoimmune diseases and preg-
nancy. In all these fields, C4d holds promise to detect patients
at risk for the consequences of antibody-mediated disease.
Moreover, the emergence of new therapeutics that inhibit
complement activation makes C4d a marker with potential
to identify patients who may possibly benefit from these
drugs.
This review provides an overview of the past, present, and
future perspectives of C4d as a biomarker, focusing on its use
in transplantation and discussing its possible new roles in
autoimmunity and pregnancy. For this purpose, a group of
experts were interviewed about the role of C4d within their
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fields of expertise and challenged to think about the following
issues:
K Will we still be using C4d in 10 years time, and if not,
what alternatives would you suggest?
K What would you like to investigate if you would receive
funding to be spent on research in the field of C4d?
K What is your take home message for readers and
listeners?
The interviews form the backbone of this review, together
with a review of the recent literature on C4d. We would like
to motivate readers to listen to the audio files that can be
found online (Supplementary Material online), which
include highlights, quotes and authors’ comments on both
the state of the art and controversies in the field of C4d.
A summary of this reviews most important points is given
in Box 1.
BIOLOGY OF C4d
The human complement system
The complement system is an ancient component of the
innate immune system. Complement activation is a non-
specific, potent force. Once activated, it makes no distinction
between self and non-self. Therefore, its activation is as tightly
controlled as its natural regulation.2 The three pathways by
which the complement system can become activated, namely,
the classical, lectin, and alternative pathway, converge at the
level of C3 and proceed into the formation of the membrane
attack complex on complement-activating surfaces, causing
direct tissue injury by perforation of the cell membrane. In
addition, potent anaphylatoxins C3a and C5a are being
formed in the process, which elicit the recruitment of other
inflammatory cells to the site of activation (Figure 1a).
The classical pathway and generation of C4d
The classical pathway of complement is initiated via binding
of its recognition molecule C1q to immune complex
deposits, antibody-antigen binding, or charged molecules.
When C1q becomes activated, it subsequently activates its
natural substrate C4. C4d is a split product of C4 activation,
without a biological function.1,4 Although C4d is mainly
interpreted as a trace of classical pathway activation, it must
be kept in mind that C4 can also be generated via the lectin
pathway. Mannose-binding lectin (MBL) or ficolins binding
to carbohydrate ligands on the surface of a wide variety of
pathogens results in activation of the lectin pathway and
cleavage of C4.5,6 Consequently, C4d may be generated
without prior antibody binding (Figure 1a).
C4d as a footprint of antibody-mediated cell injury
It is interesting that C4d is a biomarker even though it is an
inactive split product of the complement cascade. C4d has
been called ‘a footprint’ of antibody-mediated tissue injury.
This nickname is based on the unusual phenomenon that
C4b, the larger molecule that C4d is derived from, has an
internal thioester in the molecule, giving it the ability to form
a covalent bond with any free hydrogen group on target cells.
When C4d is cleaved from C4b, the covalent bond between
C4d and the tissue remains intact. Covalently bound C4d has
a much longer half-life, and therefore remains at the site of
complement activation, whereas antibodies bind to tissue by
hydrostatic, van der Waals type of interactions. The ‘footprint
effect’ of the internal thioester of C4d (Figure 1b) becomes
strikingly apparent when the blood stream can clear all
soluble/weakly bound molecules quickly, as happens with
antibodies at endothelial surfaces. Covalently bound C4d will
not be affected, because it is anchored tightly to the tissue
and therefore serves as a footprint of antibody-mediated
tissue injury.
THE DISCOVERY OF C4d AS A CLINICAL MARKER FOR AMR
From hyperacute rejection episodes it was known that donor-
specific antibodies (DSAs), either anti-human lymphocyte
antigen (HLA) or anti-ABO, had the capacity to destroy a
graft.7–9 However, although there was speculation about a
role for allo-antibodies in other forms of rejection apart from
the hyperacute form, it was unclear what fraction of acute
rejection episodes had a humoral component and how to
recognize that an AMR was present. The publications of
Feucht et al.10,11 in the early nineties marked a turning point
in the history of solid organ transplantation. Feucht showed
that patients with suspected antibody-mediated injury in the
renal graft had a linear C4d staining pattern in peritubular
capillaries and that the presence of C4d was associated with
impaired graft function. Remarkably, these initial publica-
tions received relatively little attention in the transplant
community.10,12,13 At the turn of the century the group of
Collins et al.14 tested for presence of C4d along with other
markers of endothelial activation or injury in renal transplant
biopsies suspected of AMR. C4d was found in each of
10 renal biopsies of patients with circulating DSA and
morphological signs suspicious of AMR, and in none of
14 controls with acute cellular rejection without detectable
DSA.14 This work embodied the connection of dots between
C4d, the presence of DSA and a selection of histomorpho-
logical features of AMR, which after four decades of an
intensive search for a marker was nothing short of
Box 1 | Summary and take home points
K C4d is a widely used marker for antibody-mediated rejection in the
kidney, heart, pancreas, and possibly lung allografts.
K In ABO-incompatible grafts, C4d is not a useful test, and may even
indicate graft accommodation.
K In pregnancy, C4d at the fetal–maternal interface indicates
antibody-mediated rejection of ‘the fetal allograft’, as was
demonstrated in antiphospholipid antibody-induced fetal loss.
K C4d shows that the complement system is involved: If complement
targeted therapies will be part of our future treatment options, a
marker such as C4d will be needed to identify patients susceptible
for those kind of (expensive) treatments.
K Alternatives for C4d are emerging (genomics, molecular
diagnostics, and endothelial transcripts) and if proven useful, effort
will be made to transform these techniques or their progeny to
practical tests.
Kidney International (2012) 81, 628–639 629
D Cohen et al.: C4d as a biomarker r ev iew
revolutionary. A few years later, the correlation with graft
survival that Feucht et al. had already reported on in 1993
was confirmed by other groups.4,15 This led to general
acceptance of the usefulness of C4d in the identification of
acute AMR. In 2003 ‘C4d’ was incorporated in the Banff
classification16 (Box 2).
C4D IN CURRENT CLINICAL PRACTICE
For the kidney a consensus was reached that a diagnosis
of AMR requires the simultaneous presence of DSA,
distinguishable histopathological findings and deposition
of C4d in peritubular capillaries (Figures 2 and 3a). Most
centers involved in the management of transplant recipients
have incorporated routine C4d staining in diagnostic
pathology evaluation of all renal allograft biopsies.16 A solid
base for regular C4d staining of biopsied allograft tissue is
now established for heart transplantation and pancreas
transplantation.17–19 For other transplanted organs such as
the lung, the usage of C4d staining is still controversial.20,21
In liver and short bowel transplantation C4d seems to have
no additional diagnostic value.22
In Box 3, guidelines are given on how to interpret various
test outcomes of C4d staining and DSA test results that
clinicians who work with C4d commonly encounter in
daily clinical practice. Furthermore, detailed information on
how a C4d stain should be best performed is given in the
Supplementary Material. Finally, Box 4 elaborates on current
treatment options for AMR.23–26
DEBATED ISSUES 1: C4D IN CHRONIC REJECTION EPISODES
Soon after the introduction of C4d in daily clinical practice,
the phenomenon of a diffuse C4d staining pattern was
frequently observed years after transplantation and was asso-
ciated with chronic changes in the graft.27,28 This was in
contrast with the idea that antibodies were only involved in
hyperacute and acute rejection episodes. The presence of C4d
in the late and chronic rejection episodes prompted clinicians
and researchers to the hypothesis that an antibody compo-
nent was present in forms of chronic rejection.
The concrete arguments that underline the role of anti-
bodies in chronic rejection are as follows: First, in experi-
mental models of non-human primates with transplanted
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Figure 1 |The complement system and C4d. (a) The classical pathway of complement is initiated via binding of its recognition molecule
C1q to immune complex deposits, antibody-antigen binding or charged molecules. When C1q becomes activated, it subsequently activates
its natural substrate C4. C4d is a split product of C4 activation, without a biological function. Although C4d is mainly interpreted as a trace of
classical pathway activation, it must be kept in mind that C4 can also be derived from the lectin pathway. Mannose-binding lectin (MBL) or
ficolins binding to carbohydrate ligands on the surface of a wide variety of pathogens results in activation of the lectin pathway and
cleavage of C4. Consequently, C4d may be generated without prior antibody binding. Classical complement activation converges with
other pathways at the level of C3 and proceeds into the formation of the membrane attack complex on complement-activating surfaces,
causing direct tissue injury by perforation of the cell membrane. In addition, potent anaphylatoxins C3a and C5a are being formed in the
process, which elicit the recruitment of other inflammatory cells to the site of activation. (b) C4d as a footprint for antibody-mediated tissue
injury. C4b, the larger molecule that C4d is derived from, has an internal thioester in the molecule, giving it the ability to form a covalent
bond with target cells. When C4d is cleaved from C4b, the covalent bond between C4d and the tissue remains intact. Covalently bound
C4d has a higher chance to remain at the site of complement activation than the antibodies themselves, which dissociate over time. C4d is
anchored tightly to the tissue and therefore acts as a footprint of antibody-mediated tissue injury.
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kidneys (with no immunosuppressive drugs) progression
to chronic graft injury and loss consistently goes through
four stages: alloantibody production, deposition of C4d in
peritubular capillaries and sometimes glomeruli, chronic
histopathological changes, and finally, graft loss.29
Second, several large (prospective) studies showed that
presence of circulating anti-HLA antibodies are associated
with late graft failure.30–32 Third, histological changes asso-
ciated with late graft loss, such as glomerular double
contours, peritubular capillary basement membrane multi-
layering, interstitial fibrosis, and fibrous intimal thickening in
arteries, are found in close association with C4d deposition in
peritubular capillaries and presence of anti-HLA antibodies:
In about 30–40% of biopsies with late graft dysfunction, C4d
can be detected in peritubular capillaries.27,32–36
On the basis of the current understanding, criteria were
proposed to diagnose chronic AMR in 2007. To establish this
diagnosis, three elements should be present:
(1) Histological evidence of chronic injury
(2) Immunopathological evidence of antibody-mediated
graft injury (C4d deposition)
(3) Evidence of antibodies reactive against the donor
However, there are several controversies surrounding chronic
AMR. Most importantly there is no clear-cut definition of
what is meant by ‘chronic’. For some it simply means burned-
Box 2 | State of the art: Banff guidelines for the diagnosis of
AMR
K The diagnosis of antibody-mediated rejection (AMR) in renal
allografts is currently based on criteria established during the Banff
conference on Allograft Pathology in 2007, which include the three
following cardinal features:
(1) Morphologic evidence of acute or chronic tissue injury
(2) Immunopathological staining for C4d in peritubular capillaries
(3) Presence of circulating antibodies to donor human lymphocyte
antigen or other antigens expressed on donor endothelial
cells.
K It is recommended that every renal, cardiac, and pancreas allograft
biopsy should be stained for C4d.
K C4d staining is considered positive only when depositions are
found in the following anatomical locations:
J Kidney: Peritubular capillaries (Figure 3a)
J Pancreas: Interacinar capillaries (Figure 3c)
J Heart: Myocardial capillaries
K C4d is scored semiquantitatively in four categories:
J No C4d staining (0% of (peritubular) capillaries)
J Minimal C4d staining (0–10% of (peritubular) capillaries)
J Focal C4d staining (10–50% of (peritubular) capillaries)
J Diffuse C4d staining (450% of (peritubular) capillaries)
K Immunofluorescence is a more sensitive method to detect C4d
than immunohistochemistry, by approximately one grade of the
scoring system.
K Although a diffuse C4d staining is defined as positive, the definition
and clinical significance of ‘minimal’ and ‘focal’ C4d staining remain
debated issues. Most experts consider a focal staining pattern as
a red flag, especially when detected on paraffin-embedded tissue
or in the presence of donor-specific antibody and/or suspicious
histopathological features.
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Figure 2 |Diagnosing acute antibody-mediated rejection. This flowchart shows that the diagnosis of acute antibody-mediated
rejection requires the presence of histological features, a positive C4d stain, and the presence of donor-specific antibodies. AMR, antibody-
mediated rejection; ATN, acute tubular necrosis; HLA, human lymphocyte antigen; tx, treatment.
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out scar formation. Others use the word in a broader sense,
thinking that there are chronic changes with some kind of
activity so that chronicity still has an ongoing active compo-
nent (and thus, a potential for treatment). Here the
advantage of C4d is that it indicates recent (weeks) activity
of an active immunological process.
It is unknown why DSAs cause acute rejection in one
patient and chronic rejection in another, or even both
sequentially in the same patient. Factors such as antibody
titer, antibody avidity, and the extent of resistance (or
accommodation) of the graft endothelium to complement
activation could be responsible for this phenomenon. More
research in this field is certainly needed, as the lack of insight
into the natural history of chronic AMR now entails that the
optimal therapy for chronic AMR remains undetermined.
DEBATED ISSUES 2: C4d-NEGATIVE AMR
Antibodies mainly damage a graft by targeting the endo-
thelium of the graft’s microcirculation. This concept is the
basis for the molecular studies performed by Sis et al.33 since
2007. These studies have elegantly uncovered a possible
new form of AMR, namely, C4d-negative AMR (which has
been described in a chronic, but not in acute settings). This
important finding is currently the most interesting challenge
for the concept of C4d as a biomarker, as the first studies
using endothelial transcripts combined with DSA show
excellent sensitivities for AMR (although less specificity than
C4d), for chronic AMR.3 As a marker of antibody interaction
with the tissue, it is not inconceivable that this or a simpler
derivative method will partly or fully replace C4d in future.
In 2007, a retrospective study of biopsies from 1320 tran-
splanted patients showed that more than 40% of cases with
transplant glomerulopathy—a histological lesion considered
relatively characteristic for chronic AMR—were C4d nega-
tive, despite the fact that anti-HLA antibodies were detected
in 73% of patients.33 This work was followed by studies
looking at mRNA levels of genes involved in endothelial
activation and injury. Interestingly, biopsies with high
expression of these endothelial transcripts in combination
ba
c d
Figure 3 |C4d staining patterns in different clinical settings.
(a) Acute AMR of a kidney graft with typical peritubular capillary
staining of C4d on paraffin-embedded tissue. (b) Glomerular
C4d in a native kidney biopsy of a patient with lupus nephritis
and thrombotic microangiopathy. (c) C4d in a pancreas graft
with typical staining of C4d in interacinar capillaries, suggestive
for AMR. (d) Placental C4d in a placenta from a patient with
antiphospholipid syndrome and an intrauterine fetal death in
this pregnancy. C4d is positive at the fetal–maternal interface
on the maternal side of the syncytiotrophoblast, suggesting
severe antibody-mediated injury leading to impaired placental
development, impaired nutrient exchange, intrauterine fetal
growth restriction, and finally, fetal death. AMR, antibody-
mediated rejection.
Box 3 | Issues for clinicians working with C4d in daily practice
1. Focal staining
(a) In paraffin-embedded tissue combined with a positive test for
donor-specific antibody (DSA) and histopathological features:
Most laboratories consider this as ‘positive for antibody-mediated
rejection (AMR)’. It is advised to treat the patient.
(b) In frozen tissue combined with a positive test for DSA and
histopathological features: This is sometimes called a ‘probable
AMR’. Most experts would consider treatment, however, prospective
studies should investigate this group further.
2. C4d positivity without detectable DSA
(a) Possible explanations:
(i) Allo-antibodies are present, but they are not detected by
standard anti-HLA assays (for example, anti-endothelial
antibodies).
(ii) Allo-antibodies are absorbed by the graft, as is sometimes shown
by reappearance of allo-antibodies in the blood after graft
nephrectomy.
(iii) Allo-antibodies are not present and C4d deposition is caused
by something else than DSA (for instance autoimmune disease,
i.e., lupus nephritis or any form of lectin pathway activation).
(b) How to proceed?
(i) In case of diffuse C4d staining in peritubular capillaries and
histological evidence for AMR: Most experts would advise to treat
the patient for AMR.
(ii) In case of focal C4d staining and histological evidence for AMR:
Check for other possible underlying diseases. If no other cause
can be found: Treat the patient for AMR.
(iii) In case of focal or diffuse C4d staining and absence of histological
changes the decision as to whether to treat for AMR is more
uncertain. Treating or close follow-up are both suitable options.
3. C4d positivity in grafts without histological abnormalities
(a) In ABO-incompatible grafts: In case of no histopathology and no
graft dysfunction: It is suggested to interpret this as ‘graft
accommodation’. No treatment is necessary, but close follow-up is
strongly advised, as it is unknown what happens with these grafts
during long-term follow-up.
(b) In positive cross-matched patients (presensitized patient), this
should not be seen as graft accommodation and is a rare and more
worrying situation than the above: In case of normal histology
and no graft dysfunction: Interpret as probable AMR and consider
treating the patient. Prospective studies on the long-term follow-up
of this group of patients are awaited.
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with circulating DSA showed concurrent histopathological
lesions of AMR (such as capillaritis, glomerulitis, transplant
glomerulopathy, and fibrosis/atrophy) and had poor out-
comes.3,37 Many of these active AMR cases would have been
missed otherwise: Only 40% of kidneys with high endothelial
gene expression and histopathological signs of chronic AMR
were C4d positive.37
So far, two groups have confirmed the concept of C4d-
negative AMR. In sensitized recipients, Loupy et al.38,39
showed that C4d or capillaritis in 3-month protocol biopsies
were risk factors for later transplant glomerulopathy, and
capillaritis was predictive even in the absence of C4d. The
other evidence came from Haas and Mirocha,40 who
investigated patients with DSAs who had a biopsy during
the first 3 months after transplantation. Patients with a C4d-
negative biopsy who were not treated for AMR had a higher
rate of progression to transplant glomerulopathy than those
who were treated for AMR post-biopsy.40
Because of these complexities a working group was
established at the 2011 Banff Conference to refine criteria
for diagnosis of chronic AMR in the kidney, and to investi-
gate whether C4d-negative AMR should be incorporated in
the Banff classification.
If there is indeed a C4d-negative form of AMR, it
presumably is due to a pathophysiological mechanism that is
complement independent. There are two types of experi-
mental studies that recently provided some insight into this
mechanism: Reed and group41 have set up an in vitro model
of cultured endothelial cells, to which allo-antibodies can be
added. The authors were able to show that allo-antibodies
themselves can alter the state of the endothelium in the
absence of complement or other inflammatory cells. In
response to allo-antibodies, endothelial cells started expres-
sing proinflammatory molecules, increased growth factor and
adhesion molecules such as E-selectin, P-selectin, ICAM-1,
VCAM-1, and CX3CL1.41 Subsequently, it was demonstrated
that adding natural killer cells or macrophages together with
antibodies to cultured endothelial cells could damage the
endothelial cells even more severely, through Fc receptor
interactions.42,43 Apparently, antibodies can induce injury
through interaction with leukocytes such as natural killer
cells, without complement as a mediator. In vivo, this has
been recently demonstrated in mouse heart allografts44 and
NK cells have been detected within glomerular and peri-
tubular capillaries in human biopsies showing AMR.45 New
diagnostic and therapeutic approaches are warranted to
approach these cases in future.
DEBATED ISSUES 3: C4D POSITIVITY AS A SIGN OF GRAFT
ACCOMMODATION
Despite the experience that preformed antibodies against
HLA- or blood group antigens due to pregnancy, blood
transfusion, or prior transplants are a major cause of
hyperacute rejection of renal allografts, the ever expanding
deceased-donor waiting list led to the development of
protocols enabling transplantation across these immunologic
barriers. Japan and North America were the first to
successfully transplant ABO-incompatible grafts in patients
who had been pretreated with improved immunosuppressive
regimens and plasmapheresis to remove preexisting anti-
bodies.46,47 The follow-up of these cases revealed some
unexpected phenomena, which served as the basis of a new
and exiting concept: Stable graft accommodation.
As it soon became apparent that recurrence of low levels
of anti-blood group antibodies occurred frequently in patients
transplanted with an ABO-incompatible graft, there was con-
cern about the development of AMR in these grafts. Not quite
unexpectedly, diffuse C4d staining of peritubular capillaries in
these biopsies was commonly found, even in protocol biopsies.
However, the fact that more than 70–80% of ABO-incompatible
grafts showed diffuse C4d positivity was a surprising finding,
especially when compared with the marginal 30–40% diffuse
positives observed in the group of patients with a positive
cross-match for anti-HLA antibodies.48–50
Strikingly, in contrast to conventional transplants where a
diffuse C4d stain is strongly associated with histological
abnormalities such as capillaritis and transplant glomerulo-
pathy, the ABO-incompatible kidneys as a rule show diffuse
C4d positivity without histological tissue injury.51,52 A recent
retrospective case–control study by Haas et al.53 indicated
that persistent C4d-positive ABO-incompatible grafts with-
out histological abnormalities are not subject to increased
graft scarring, transplant glomerulopathy, or reduced renal
function within the first year after transplantation.53 More-
over, ABO-incompatible grafts with persistent diffuse C4d
positivity had significantly less chronic damage after 1 year.
These puzzling observations can possibly be understood in
the light of accommodation, in which a graft acquires
resistance to humoral injury and continues to function well
despite the constant presence of low levels of antibodies
against the ABO antigens on the endothelium.
Box 4 | Therapy options for AMR
Although much progress has been made in understanding the etiology of
antibody-mediated rejection (AMR) and diagnosing the condition,
it remains to be elucidated what treatment option is most beneficial.
AMR is relatively unresponsive to therapies targeting T-lymphocytes
used in acute cellular rejection such as steroids, cyclosporine, tacrolimus,
and sirolimus. This issue has not been addressed in a randomized
controlled fashion so far. Therapeutic strategies reported in the
literature in case reports, case series, and cohort studies are the
following:23
(1) The suppression of the T-cell–dependent antibody response
(steroids, cyclosporine, tacrolimus, and sirolimus)
(2) The removal of donor reactive antibody (plasmapheresis)
(3) The blockade of the residual allo-antibody (IvIg)
(4) The depletion of naive and memory B cells (rituximab)
(5) Inactivation of plasma cells (bortezomib)24,25,26
(6) The blockade of complement component C5 by monoclonal
antibodies (eculizumab)
There is large variability between transplant centers around the
world in their specific therapeutic approach, but generally a combination
of IvIg, plasmapheresis, and recently, rituximab is used. Trials (especially
randomized controlled trials) investigating the effects of targeted
complement blockade are awaited.
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An underlying mechanism that might explain in part
the development of graft accommodation, as suggested by
Park et al.,54 could be the upregulation of complement
regulatory proteins in endothelial cells, by which the initial
activation of complement due to antibody binding is blocked
at a point later in the cascade. This could explain the
persistent presence of C4d without signs of microvascular
injury,55 although why this happens frequently in the setting
of ABO incompatibility, but at most rarely, in the setting
of HLA-mismatched patients is poorly understood at the
moment. Still, just as antibody-mediated graft injury cannot
be completely accounted for by complement activation,37
complement inhibition alone does not appear to prevent
chronic antibody-mediated graft injury.56
In conclusion, the common finding of C4d positivity in
ABO-incompatible grafts without histological abnormalities
currently forces pathologists to look more closely into the
histology when trying to diagnose AMR in an ABO-
incompatible graft, as a C4d stain in this group appears to
signify something different than ‘rejection’ and cannot be
reliably used as a diagnostic tool.
NEW FIELDS 1: C4D AND AMR IN OTHER TRANSPLANTED
SOLID ORGANS
After the recognition of C4d as a tool to detect AMR in the
transplanted kidney, this concept was soon translated to
virtually all other transplanted solid organs. The transplanted
organs in which the significance of C4d deposition has been
most studied are the heart, lung, liver, and pancreas.
C4d in cardiac transplantation
Many groups have shown that linear C4d deposition
along myocardial capillaries is a reliable-specific marker for
antibody-mediated cardiac allograft rejection.17,57,58 More-
over, in line with earlier studies in the kidney, it was also
shown that C4d positivity in the heart is an independent
predictor of cardiac dysfunction and of cardiac mortality.19,59
The International Society for Heart and Lung Transplanta-
tion recommends that a diagnosis of AMR in a cardiac
allograft can be justified when there is clinical evidence
of graft dysfunction, histological evidence of acute capillary
injury, and immunopathological evidence for C4d capillary
positivity on endomyocardial biopsies. According to the
International Society for Heart and Lung Transplantation,
positive histological features indicative of AMR are necessary
to warrant C4d staining.60 However, a recent publication
by Fedrigo et al.19 casted doubt upon this approach, and
suggested that C4d should instead be performed routinely on
endomyocardial graft biopsies: The authors investigated 985
endomyocardial biopsies from 107 heart transplant recipients
by staining them immunohistochemically for C4d. Intragraft
C4d capillary deposition was present in 34%, but only
7% had AMR based on the International Society for Heart
and Lung Transplantation criteria. Interestingly, C4d posi-
tivity, even without the presence of DSA, impaired graft
function, or histological features of AMR, was independently
associated to a higher mortality risk (unadjusted hazard ratio
in patients with positive C4d staining, without DSA or loss of
graft function).19 This study supports the concept of routine
C4d staining, as no correlation between histology alone and
clinical status could be elicited. In response to the emerging
data, the Banff group reached consensus recommending
specific time points to monitor DSA as well as C4d staining
on every cardiac allograft biopsy, interpreting C4d staining
only in myocardial capillaries and scoring as diffuse (450%
of capillaries), focal (o50%), or negative, but accepting only
diffuse staining as positive.61
C4d in lung transplantation
Hyperacute and acute AMR episodes are well documented in
lung transplantation: In such cases, diffuse alveolar damage,
neutrophilic infiltrates, and post-transplant pulmonary
capillary injury are typical histological findings that are
distinct from cellular rejection and less responsive to cortico-
steroid treatment. C4d deposition in such cases was detected
in several studies, mainly in septal capillaries, and was asso-
ciated with parenchymal injury, clinical status, and the
presence of DSA or anti-endothelial antibodies.21,62,63
However, a consistent anatomical deposition pattern of
C4d in the lung was more problematic to identify than in
the kidney (peritubular capillaries), the heart (myocardial
capillaries), or even the pancreas (interacinar capillaries). A
study by Wallace et al.64 could not describe any specific
staining pattern in 68 lung allograft biopsy specimens using
currently available techniques. Focal nonspecific staining
occurred just as often in cases with suspected AMR compared
with more chronic forms of rejection.64 Probably, the
anatomy of the lung complicates pattern recognition, as the
frequent occurrence of alveolar hemorrhage and septal
damage give rise to nonspecific staining patterns, which
makes it hard to score pulmonary allograft biopsies.
Compared with kidney transplants, the role of AMR and
C4d in chronic pulmonary allograft rejection (bronchiolitis
obliterans syndrome) is heavily debated. Magro et al.65
reported on evident C4d deposition in a series of 13 single-
lung transplant patients with bronchiolitis obliterans syn-
drome, who had circulating anti-endothelial antibodies.
Westall et al.66 investigated septal capillary C4d staining early
after lung transplantation. Complement staining was not
associated with acute cellular or chronic rejection, or with
morphological features of AMR, but in a subgroup analysis
the authors identified nine cases who developed early
bronchiolitis obliterans syndrome. Interestingly, these cases
showed significant lung allograft C3d/C4d deposition along
with light-microscopic features suggestive of AMR, suggest-
ing that C4d staining could potentially have a role in the
identification of patients at risk of developing a chronic
humoral form of pulmonary allograft rejection.66 Although
these results point into the direction of antibody-mediated
processes in chronic pulmonary graft rejection, these results
should be replicated in larger cohorts to make any definitive
statement.
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In conclusion, the presence in one patient of both anti-
HLA antibodies or anti-endothelial antibodies and patho-
logical findings suspicious for AMR (including C4d staining)
should be seen as a strong evidence for AMR of the
pulmonary allograft, but there is not enough evidence for
C4d as a marker for AMR in the lung graft to perform
routine C4d staining on all pulmonary allograft biopsies.
C4d in pancreas transplantation
Few studies are available describing the histological and
immunohistochemical features of rejection episodes of the
pancreas, compared with other transplanted solid organs.
The first large cohort appeared in 2009 including 27 pancreas
biopsies, showing that C4d deposition in interacinar
capillaries (Figure 3c) is associated with de novo DSA
and impaired graft outcome, suggestive of AMR. These
results were followed by a study that reported on a
correlation between interacinar C4d staining with several
serum and urine pancreas rejection markers. A third study
discussing the role of AMR in simultaneous pancreas–kidney
transplantation was performed in 2010, confirming that
presence of C4d was associated with impaired pancreas
survival.18
In all studies, only C4d staining in interacinar capillaries
of the pancreas was demonstrated to correlate with circu-
lating DSA. Coinciding histological parameters included
capillaritis, edema, active septal inflammation, acinar inflam-
mation, and acinar cell injury/necrosis. These findings led
to the inclusion of C4d staining in the Banff classification
for pancreas transplant pathology.61 However, to date no
prospective studies have been performed evaluating the
effect of treatment targeted at antibody-mediated injury, or
reporting on long-term follow up of C4d-positive vs. C4d-
negative pancreas grafts. These will be future challenges.
Meanwhile, it is advised to stain all pancreas biopsies for C4d,
with diffuse positive staining as indicative of AMR and focal
positivity as suspected for AMR.
C4d in liver transplantation
In the liver there are several excellent studies available, but
results are variable as well as the C4d staining pattern: In
different studies, emphasis is being put on sinusoidal
staining, portal vein staining, central vein staining, and even
stromal staining in the portal tract. There seems to be no
agreement.22 And even beyond that, studies have reported
significant C4d staining in cases that are not directly
related to rejection, such as autoimmune hepatitis, or viral
hepatitis. There might be a different role for complement in
rejection of the liver, as many complement components
are produced in this organ. The endothelium of the liver
could thus be more resistant to complement-induced
damage. In fact, this may partly explain the relatively low
frequency of liver rejection in general, as well as the
possibility of ABO-incompatible transplantation. Overall, in
liver transplantation C4d is not a useful diagnostic marker to
detect AMR.
NEW FIELDS 2: C4d IN NATIVE RENAL DISEASE
The detection of capillary C4d in kidney transplants was
the logical consequence of previous studies of the
classical complement cascade in normal and diseased native
kidneys,67 including also other mammalian kidneys.68 After
the discovery of C4d as a biomarker in transplantation, many
studies have sought evidence for C4d deposition in native
kidneys, mainly in the setting of autoimmunity.
In native kidney disease, peritubular capillary C4d staining
was investigated in many forms of glomerulonephritis,67,69–73
where peritubular capillary C4d staining was virtually never
observed. The only exception was lupus nephritis, in which
granular peritubular capillary staining has been rarely
described, which should be kept in mind when a diagnosis
of AMR in a transplanted systemic lupus erythematosus
(SLE) patient is considered. Recurrence of the original disease
should then be ruled out.
Glomerular C4d deposition on the other hand is a
relatively common finding in native-diseased kidneys. Xing
et al. recently investigated which complement pathways were
involved in anti-neutrophil autoantibody-associated vasculi-
tis. Interestingly, they detected glomerular C4d only in a
small subgroup of patients with anti-neutrophil autoanti-
body-negative pauci-immune glomerulonephritis, whereas in
the anti-neutrophil autoantibody-positive patients, it was
absent.73 The authors could not identify glomerular deposi-
tion of C1q and most C4d-positive cases were also MBL
positive. This is an example of C4d positivity that does not
seem to be linked primarily to classic pathway activation.
MBL positivity may instead be associated with exposure of
carbohydrate (sugar) moieties in damaged glomeruli or
glomerular basement membrane, an infectious pathogenesis,
or just a consequence of tissue damage or remodeling.
Although interesting from an etiological point of view, it is
not likely that C4d will be used as a diagnostic marker in
anti-neutrophil autoantibody-associated vasculitis in the near
future.
In lupus nephritis, glomerular C4d deposition can be
detected in the majority of cases with a full-house immuno-
fluorescence pattern, as a result of immune complex
deposition (Figure 3b).67,74 In one study, biopsies of patients
with lupus nephritis with prominent diffuse glomerular C4d
staining had detectable glomerular microthrombi signifi-
cantly more often than biopsies of patients with focal or mild
C4d staining.71 This relation between thrombotic micro-
angiopathy and glomerular C4d has been confirmed in renal
biopsies of patients with antiphospholipid syndrome, a
similar antibody-mediated autoimmune disease leading to
endothelial damage and thrombosis in all vascular beds.75
Apparently, uncontrolled or abundant complement activa-
tion can cause severe damage to the glomerular endothelium
to such an extent that a thrombotic microangiopathy
can develop. This is in line with the occasionally observed
thrombotic microangiopathy in cases of C4d-positive acute
AMR.76 Furthermore, this mechanism also has a role in
atypical Hemolytic Uremic Syndrome, where a genetic defect
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in complement regulation causes widespread microthrom-
bosis.77 In the setting of thrombotic microangiopathies
independent of the underlying disease, performing a C4d
stain might help clinicians understand the mechanisms of
renal microvascular thrombosis. A positive C4d stain could
indicate that complement is involved, and could even guide
future treatment, for instance, with complement inhibitors.
However, this needs further basic study, and its clinical utility
must await trials of complement inhibitory therapies.
NEW FIELD 3. C4d IN PREGNANCY: ANTIBODY-MEDIATED
PREGNANCY LOSS?
The analogy between pregnancy and transplantation was
made as early as 1953, when Peter Medawar introduced
the concept of ‘the fetal allograft’.78 Failure of placentation,
which may be triggered by immune mechanisms, underlies
a spectrum of common pregnancy disorders.79 Defective
placentation is known to occur in a substantial proportion
of cases of early pregnancy loss, with reduced trophoblast
invasion into both the decidua and spiral arteries.80 Similar
to the primary defect in preeclampsia, fetal growth restriction
and still birth are the resultant reduction in uteroplacental
blood flow. However, in settings of recurrent miscarriage
(43 consecutive miscarriages) this might be different: The
more miscarriages a women experiences, the higher the
chance of an underlying maternal condition.81
In certain autoimmune diseases, such as SLE and anti-
phospholipid syndrome, recurrent early and late miscarriage
occur up to 20 times more often than in the normal
population, and placental insufficiency leading to pree-
clampsia and fetal growth restriction are also of increased
prevalence.82,83 In antiphospholipid syndrome, it has been
established that pathogenic antibodies bind to trophoblast.84
The question is: Can these pregnancy losses and other
complications be interpreted as ‘antibody-mediated’? A
recent study by Cohen et al demonstrated that complicated
pregnancies of patients with SLE and antiphospholipid
syndrome share several pathophysiological aspects with
AMR85 (Figure 4). Interestingly, placental C4d was detectable
in the majority of SLE and antiphospholipid syndrome cases
(460%) in a diffuse staining pattern at the fetal-maternal
interface (Figure 3d), whereas in normal pregnancies C4d
was always negative. Excessive placental C4d was related
to impaired fetal outcome due to fetal loss or due to
prematurity in the setting of preeclampsia. These studies
extend previous work showing increased C4d in placentas
from patients with antiphospholipid syndrome,86 and they
argue that C4d is associated with clinical outcomes. Both
antiphospholipid antibodies and DSA seem to bind at the
interface where cells from the one individual (mother or
host) meet the other (fetus or graft), and C4d functions as a
footprint for antibody-mediated tissue injury. These results
point at a role for complement in disease pathogenesis and
possible role for C4d as a biomarker to verify that this
pathway is activated in pregnancy complication. Identifica-
tion of patients with C4d and antibody-mediated pregnancy
morbidity, for instance after a late pregnancy loss or
following multiple miscarriages, might direct their therapy.
Antibody-mediated
rejection of an
allograft
Antibody-mediated
rejection of the
‘fetal allograft’
• Antibodies involved:
antiphospholipid antibodies,
possibly also anti-paternal-
HLA antibodies
• C4d: Positive at the
frontier where the mother
meets the fetus (placental
syncytiotrophoblast cells)
• Associated with adverse
fetal outcome (recurrent
miscarriage, intrauterine fetal
death, preeclampsia, and
hemolysis, elevated liver enzymes
and low platelets syndrome)
• Antibodies involved: Anti-
  HLA, anti-endothelium,
    anti-blood group
• C4d: Positive at the
 frontier where the host
   meets the donor
   (peritubular capillary
   endothelium)
  • Associated with
   adverse graft outcome
  (hyper) acute humoral
rejection, chronic 
humoral rejection
Figure 4 |Analogy between AMR and antibody-mediated pregnancy loss. In this scheme the analogy between antibody-mediated
rejection of a transplanted graft and ‘antibody-mediated pregnancy loss’ is schematically shown. HLA, human lymphocyte antigen.
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To take this concept further, a similar mechanism could
have a role in other pregnancy-related disorders with a
possible immunological background and a clinical course of
miscarriages, fetal death, or early delivery. Indeed, reports are
slowly emerging investigating the role of complement and
C4d in preeclampsia and hemolysis, elevated liver enzymes
and low platelets—syndrome87 and spontaneous early
delivery.88 In a cohort of women with severe preecla-
mpsia with and without underlying SLE/antiphospholipid
syndrome (the PROMISSE study), Salmon et al.87 recently
showed that not only excessive activation of complement, but
also inadequate regulation could contribute to preeclampsia.
The authors identified several mutations in complement
regulatory genes in a subgroup of preeclamptic women,
among which a new mutation involved in the regulation of
C4 activation. These striking observations support the concept
that C4 activation at the fetal–maternal interface is an essential
mediator of both fetal loss and preeclampsia and that insufficient
regulation of C4 leads to a more severe phenotype.
Although the diagnostic value of placental C4d has not
been tested in a prospective manner, these studies would be
helpful to investigate whether a positive placental C4d stain
is a risk factor of a future complicated pregnancy.
CONCLUSION: PROS AND CONS FOR C4D AS A BIOMARKER
IN TRANSPLANTATION, AUTOIMMUNITY, AND PREGNANCY
The introduction of C4d as a biomarker into the standard
work-up of renal transplant biopsies has provoked an
enormous amount of insight into the role of antibodies in
different forms of allograft rejection. C4d is now one of the
core diagnostic tools to identify AMR, and is being used in
virtually all transplant centers around the world. The vast
amount of research into the deposition patterns of C4d in
different clinical settings, such as in the kidney, heart,
pancreas, and lung transplantation, has taught us that
antibodies contribute largely to both acute and chronic
rejection episodes.
In analogy with solid organ transplantation, C4d has
recently been demonstrated in pregnancy, in particular in the
setting of ‘antiphospholipid antibody-mediated fetal loss’ and
preeclampsia. In autoimmune settings C4d might have a role
in identifying patients at risk of developing thrombotic com-
plications. More research will nevertheless be needed to discover
the full extend of C4d as a biomarker in these new fields.
This review has shown that there are certain drawbacks
of using C4d. The difficulties of interpreting focal staining
patterns, the relatively low sensitivity of C4d as a marker for
AMR in late renal allograft biopsies, and its lack of utility as a
marker for antibody-mediated injury in biopsies of ABO-
incompatible allografts suggests that C4d has lost some of its
magic during the past decade. However, most experts agree
Box 5 | Pros and cons for C4d as a biomarker
Pro C4d
C4d staining is relatively inexpensive
C4d staining is easy to perform in basic laboratories
A diffuse staining pattern is relatively easy to interpret
C4d gives very few false positives (it is relatively specific)
C4d shows that the complement system is involved: If complement
targeted therapies (eculizumab) will be part of our future treatment
options, a marker such as C4d will be needed to identify patients
susceptible for those kind of (expensive) treatments.
There are currently no reliable (prospectively tested) alternatives
available
Contra C4d
C4d scoring is subjective and the issue of focal staining and C4d/donor-
specific antibody discrepancies will not be solved
C4d is not sensitive for chronic (or chronic/active) antibody-mediated
rejection
C4d is not helpful in ABO-incompatible grafts
Alternatives for C4d are emerging (genomics, molecular diagnostics,
and endothelial transcripts) and if proven useful, great effort will
be made to transform these techniques or their progeny into practical
tests
Box 6 |What would you like to investigate if you would
receive funding to be spent on research in the field of C4d?
K Robert Colvin: ‘Understand the mechanism of accommodation.
There must be a mechanism that we can intervene with. And then
I would like to try to find out if it is possible to induce the same
endothelial state in the presence of anti-HLA antibodies’.
K Mohamed Daha: ‘I want to understand the effect of modulated and
injured tissue to complement activation. In addition, I would like
to know what local production of factors that control the
complement system do, and see if we can influence them to
control disease’.
K Cynthia Drachenberg: ‘One of the things that I find extremely
puzzling is the contrast between acute AMR and chronic AMR. How
do endothelial cells cope with this in the chronic setting and why
do they behave so differently than in the acute form of AMR?’
K Mark Haas: ‘What would be nice to do is to look at the genomics of
ABO-incompatible grafts with no histologic signs of rejection, and
see how this differs from AMR meeting current Banff criteria, from
C4d positivity without histologic findings of rejection in non
ABO-incompatible settings, and also what genomic changes have
occurred compared to ABO-incompatible base-line biopsies.’
K Volker Nickeleit: ‘I want to do a large prospective clinico-
pathological study with thousands of patients, protocol biopsies
and regular monitoring of anti-HLA antibodies to find out answers
to many unanswered questions we struggle with in daily clinical
practice’.
K Banu Sis: ‘I want to study the molecular phenotypes of early acute
AMR in presensitized patients and C4d positive ABO-incompatible
kidneys and compare molecular mechanisms of acute AMR to
chronic AMR. Subtle molecular changes may help us to intervene
before irreversible tissue injury takes place.’
K Ming-hui Zhao: ‘Recent advances on complement research provide
us a chance to rethink the role and mechanism of complement
played in many native kidney diseases. C4d is not always a
reflection of classical pathway of complement activation, but can
be MBL derived too. I would like to investigate the different roles
for classical and MBL pathway-activation further in the setting of
autoimmune renal disease’.
K Jane Salmon: ‘The most elegant approach would be to look at C4d
in pregnancy in every possible direction in well-phenotyped
patients with different pregnancy outcomes. Such a study would
include next generation sequencing to identify variants of
complement and complement regulatory proteins, measurement
of C4d on erythrocytes and complement activation products in
blood through pregnancy, and assessment of C4d deposition in
placental tissues. Analyses would define pathways and predictors. ’
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that if complement targeted therapies will be part of our
future treatment options, a marker such as C4d will be
needed to identify patients susceptible for those kind of
expensive treatments. Taken together, with its unique ability
to act as a footprint for antibody-mediated injury, C4d will
likely remain to have a prominent role in transplantation,
and possibly in pregnancy and autoimmunity (Box 5).
Finally, we would like to encourage readers to listen to the
audio files, in which a group of experts in the field of C4d
give their answers to the questions raised in the introduction
(Box 6 and Supplementary Material online).
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